BTCY - Biotricity Inc. Stock Price, Fair Value and News

1.05USD0.00 (0.00%)Delayed

Market Summary

USD1.050.00

Delayed

0.00%

BTCY Stock Price

View Fullscreen

BTCY RSI Chart

BTCY Valuation

Market Cap

9.7M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

0.84

EV/EBITDA

-0.82

Price/Free Cashflow

-1.31

BTCY Price/Sales (Trailing)

BTCY Profitability

Operating Margin

65.52%

EBT Margin

-125.43%

Return on Equity

-15.62%

Return on Assets

-265.83%

Free Cashflow Yield

-76.18%

BTCY Fundamentals

BTCY Revenue

Revenue (TTM)

11.6M

Rev. Growth (Yr)

20.89%

Rev. Growth (Qtr)

2.82%

BTCY Earnings

Earnings (TTM)

-14.6M

Earnings Growth (Yr)

37.83%

Earnings Growth (Qtr)

23.92%

Breaking Down BTCY Revenue

Last 7 days

-14.6%

Last 30 days

-17.3%

Last 90 days

8.3%

Trailing 12 Months

-72.7%

How does BTCY drawdown profile look like?

BTCY Financial Health

Current Ratio

0.21

BTCY Investor Care

Shares Dilution (1Y)

8.83%

Diluted EPS (TTM)

0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.6M	10.6M	11.1M	11.6M
2022	7.7M	7.9M	8.5M	9.0M
2021	3.4M	4.7M	5.8M	6.7M
2020	1.4M	1.5M	1.9M	2.6M
2019	414.6K	724.0K	952.2K	1.2M
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biotricity Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 29, 2021	rosa david a	acquired	-	-	27,174	-
Nov 29, 2021	betts norman m.	acquired	-	-	54,348	-
Oct 11, 2021	rosa david a	sold	-10,119	3.05	-3,318	-
Oct 08, 2021	rosa david a	sold	-30,333	3.1994	-9,481	-
Oct 07, 2021	rosa david a	sold	-53,119	3.0833	-17,228	-
Sep 16, 2021	rosa david a	sold	-119,915	3.4284	-34,977	-
Sep 15, 2021	rosa david a	sold	-20,421	3.2695	-6,246	-
Apr 07, 2020	kennedy patricia j	acquired	-	-	125,000	-
Apr 07, 2020	betts norman m.	acquired	-	-	125,000	-

Which funds bought or sold BTCY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	6,764	33,371	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	23.00	105	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-114	-	-%
May 15, 2024	AE Wealth Management LLC	sold off	-100	-36,640	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-73.01	-4,238	2,256	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	1,000	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	3,961	17,763	-%
May 13, 2024	FMR LLC	sold off	-100	-20.00	-	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-22,000	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	19,227	94,847	-%

Are Funds Buying or Selling BTCY?

Are funds buying BTCY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BTCY

No. of Funds

Recent SEC filings of Biotricity Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	424B3	Prospectus Filed
May 15, 2024	S-3/A	S-3/A
May 15, 2024	EFFECT	EFFECT
May 15, 2024	EFFECT	EFFECT
May 09, 2024	S-3	S-3
May 08, 2024	S-3	S-3
May 03, 2024	8-K	Current Report
Apr 25, 2024	RW	RW
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	424B3	Prospectus Filed

Peers (Alternatives to Biotricity Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Biotricity Inc. News

Latest updates

Biotricity Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.8%	2,972,972	2,891,297	3,020,765	2,742,435	2,459,181	2,381,389	2,056,052	2,148,742	1,930,108	1,807,309	1,764,110	1,187,033	1,001,252	744,585	451,898	362,920	381,899	345,906	327,000	161,700	117,640
Cost Of Revenue	-9.8%	804,986	892,019	1,104,061	1,207,734	1,057,215	1,101,152	830,923	708,105	1,105,271	672,711	594,029	455,173	859,363	609,296	201,342	585,617	100,782	114,216	150,586	-	27,504
Gross Profit	8.4%	2,167,986	1,999,278	1,916,704	1,534,701	1,401,966	1,280,237	1,225,129	1,440,637	824,837	1,134,598	1,170,081	731,860	141,889	135,289	250,556	-222,697	281,117	231,690	176,414	-106,920	90,136
Operating Expenses	-17.6%	3,449,760	4,184,951	4,233,190	4,988,306	5,240,424	5,309,224	5,313,791	5,270,798	5,560,137	6,303,424	4,172,597	3,978,021	4,019,793	2,994,338	3,619,236	4,263,822	2,627,567	2,239,804	2,266,015	1,717,887	2,262,384
S&GA Expenses	-14.1%	2,996,804	3,487,331	3,520,215	4,284,977	4,363,964	4,480,310	4,492,615	4,641,345	4,659,638	5,677,786	3,583,600	3,426,525	3,338,382	2,591,998	3,195,353	3,780,248	2,179,928	2,021,279	2,052,519	1,409,503	1,861,113
R&D Expenses	-35.1%	452,956	697,620	712,975	703,329	876,460	828,914	821,176	629,453	900,499	625,638	588,997	551,496	681,411	402,340	423,883	483,575	447,639	218,525	213,496	308,384	401,271
EBITDA Margin	18.8%	-1.01	-1.24	-1.43	-1.74	-2.02	-2.45	-3.40	-3.64	-3.93	-4.01	-3.26	-3.78	-5.54	-	-	-	-	-	-	-	-
Interest Expenses	4.9%	790,080	753,268	660,512	633,818	413,402	403,551	388,388	-	-	-	-	-	-	-	-	-400	-	-	-	-	-
Earnings Before Taxes	23.9%	-2,808,091	-3,690,840	-3,412,882	-4,672,228	-4,517,115	-4,692,548	-4,776,252	-5,611,839	-7,109,649	-10,752,890	-5,656,099	-5,471,544	-3,900,245	-2,962,207	-3,157,179	-4,598,222	-2,371,005	-2,008,114	-2,089,601	-1,824,806	-2,172,248
EBT Margin	14.4%	-1.25	-1.47	-1.63	-1.94	-2.17	-2.61	-3.56	-3.81	-4.33	-4.48	-3.83	-4.58	-5.71	-	-	-	-	-	-	-	-
Net Income	23.9%	-2,808,091	-3,690,840	-3,412,882	-4,672,228	-4,517,115	-4,692,548	-4,776,252	-5,611,839	-7,109,649	-10,752,890	-5,656,099	-5,374,936	-3,900,245	-3,155,424	-3,157,179	-4,598,222	-2,371,005	-2,008,114	-2,089,601	-1,824,806	-2,172,248
Net Income Margin	14.4%	-1.25	-1.47	-1.63	-1.94	-2.17	-2.61	-3.56	-3.81	-4.32	-4.46	-3.85	-4.61	-5.78	-	-	-	-	-	-	-	-
Free Cashflow	45.4%	-1,305,966	-2,390,036	-1,832,118	-1,878,268	-3,179,465	-4,450,810	-4,039,395	-4,755,102	-4,497,584	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-19.6%	5,486	6,824	6,144	6,511	6,647	8,053	12,150	16,678	21,045	13,952	2,767	4,438	5,140	2,068	1,389	2,004	5,529	1,058	1,047	491	473
Current Assets	-24.1%	3,932	5,178	4,401	4,720	4,794	6,752	10,847	15,323	19,610	13,946	2,745	4,322	4,942	1,828	1,124	1,659	5,182	661	601	458	440
Cash Equivalents	-92.9%	85.00	1,200	51.00	570	451	2,498	7,208	12,067	16,790	11,694	202	2,202	3,324	470	65.00	950	4,354	43.00	48.00	64.00	26.00
Inventory	-3.7%	2,049	2,128	2,216	2,337	1,932	1,854	1,431	843	360	118	180	272	95.00	179	236	86.00	98.00	33.00	40.00	25.00	126
Net PPE	-8.0%	17.00	19.00	20.00	22.00	23.00	24.00	26.00	27.00	29.00	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-0.3%	32,214	32,295	29,556	26,356	22,129	18,677	18,710	18,823	18,726	6,207	13,367	11,271	15,847	9,481	6,374	5,005	7,442	5,956	4,312	2,268	1,324
Current Liabilities	4.5%	18,619	17,824	15,098	11,161	7,291	4,389	4,577	4,867	4,829	5,215	12,290	10,490	8,443	7,106	3,821	3,803	6,538	5,789	4,092	2,268	-
Shareholder's Equity	-	-	-	-	-	-	-	-	-	2,319	7,745	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-2.5%	-123,100	-120,100	-116,172	-112,570	-107,713	-102,965	-98,061	-93,037	-87,055	-79,712	-68,715	-62,817	-57,033	-52,914	-49,758	-46,364	-41,531	-39,137	-37,129	-35,039	-33,216
Additional Paid-In Capital	2.4%	95,561	93,338	93,012	92,844	92,297	92,335	91,913	91,507	85,874	308	57,192	56,299	308	230	45,677	44,015	40,547	34,993	34,296	33,890	32,595
Shares Outstanding	8.1%	9,259	8,566	51,048	8,508	8,636	8,643	51,441	49,810	7,291	6,837	6,516	6,021	6,173	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	32,626	-	-	-	114,850	-	-	-	31,498	-	-	-	14,261	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	45.4%	-1,305	-2,390	-1,832	-1,878	-3,179	-4,450	-4,039	-4,755	-4,487	-3,239	-2,681	-3,579	-2,971	-2,136	-2,393	-2,952	-2,118	-1,462	-1,328	-1,157	-1,392
Share Based Compensation	4.2%	170	163	211	282	63.00	153	149	487	101	170	156	311	14.00	230	233	1,689	155	155	339	351	373
Cashflow From Investing	-	-	-	-	-	-	-	-	-1*	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-94.3%	195	3,429	1,329	1,997	1,110	-272	-833	155	9,619	14,813	581	2,586	5,439	2,604	1,574	-585	6,661	1,474	1,330	1,528	1,238
Dividend Payments	-	-	-	-	-	-	-	-	-	397	166	205	32.00	295	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BTCY Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUE	$ 2,972,972	$ 2,459,181	$ 8,885,034	$ 6,896,622
Cost of Revenue	804,986	1,057,215	2,801,066	2,989,290
NET REVENUE	2,167,986	1,401,966	6,083,968	3,907,332
EXPENSES
Selling. general and administrative expenses	2,996,804	4,363,964	10,004,350	13,336,888
Research and development expenses	452,956	876,460	1,863,551	2,526,550
TOTAL OPERATING EXPENSES	3,449,760	5,240,424	11,867,901	15,863,438
LOSS FROM OPERATIONS	(1,281,774)	(3,838,458)	(5,783,933)	(11,956,106)
Interest expense [Note 5, 6 and 9]	(790,080)	(413,402)	(2,203,860)	(1,205,342)
Accretion and amortization expenses [Note 5,6]	(422,706)	(51,061)	(1,576,345)	(151,970)
Change in fair value of derivative liabilities [Note 8]	(326,683)	(99,705)	(244,014)	(469,971)
Gain (loss) upon convertible promissory notes conversion and redemption	2,148	5,391	15,280	(85,537)
Other (expense) income [Note 13]	11,004	(119,880)	(118,941)	(116,989)
NET LOSS BEFORE INCOME TAXES	(2,808,091)	(4,517,115)	(9,911,813)	(13,985,915)
Income taxes
NET LOSS BEFORE DIVIDENDS	(2,808,091)	(4,517,115)	(9,911,813)	(13,985,915)
Adjustment: Preferred Stock Dividends	(237,904)	(230,374)	(617,043)	(690,330)
NET LOSS ATTRIBUTABLE TO COMMON STOCKLHOLDERS	(3,045,995)	(4,747,489)	(10,528,856)	(14,676,245)
Translation adjustment	(204,501)	(72,823)	(99,091)	625,698
COMPREHENSIVE LOSS	$ (3,250,496)	$ (4,820,312)	$ (10,627,947)	$ (14,050,547)
LOSS PER SHARE, BASIC	$ (0.339)	$ (0.546)	$ (1.191)	$ (1.699)
LOSS PER SHARE, DILUTED	$ (0.339)	$ (0.546)	$ (1.191)	$ (1.699)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	8,979,430	8,690,506	8,842,890	8,635,900
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	8,979,430	8,690,506	8,842,890	8,635,900

BTCY Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Mar. 31, 2023
CURRENT ASSETS
Cash	$ 85,094	$ 570,460
Accounts receivable, net	1,573,583	1,224,137
Inventories [Note 3]	2,048,910	2,337,006
Deposits and other receivables	224,895	588,599
Total current assets	3,932,482	4,720,202
Deposits [Note 10]	85,000	85,000
Long-term accounts receivable	135,560	96,344
Property and equipment [Note 12]	17,041	21,506
Operating right of use assets [Note 10]	1,316,135	1,587,492
TOTAL ASSETS	5,486,218	6,510,544
CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	7,558,745	5,042,476
Convertible promissory notes and short term loans [Note 5]	7,922,097	4,774,468
Term loan, current [Note 6]	1,800,000
Derivative liabilities [Note 8]	928,333	1,008,216
Operating lease obligations, current [Note 10]	409,702	335,608
Total current liabilities	18,618,877	11,160,768
Federally guaranteed loans [Note 7]	870,800	870,800
Term loan [Note 6]	10,533,425	12,178,809
Derivative liabilities [Note 8]	1,139,293	759,065
Operating lease obligations [Note 10]	1,051,321	1,386,487
TOTAL LIABILITIES	32,213,716	26,355,929
STOCKHOLDERS’ DEFICIENCY
Common stock, $0.001 par value, 125,000,000 shares authorized as of December 31, 2023 and March 31, 2023. Issued and outstanding common shares: 9,258,957 and 8,508,052 as of December 31, 2023 and March 31, 2023, respectively, and exchangeable shares of 160,672 and 244,458 outstanding as at December 31, 2023 and March 31, 2023, respectively [Note 9]	9,420	8,753
Shares to be issued, 3,955 shares of common stock as of December 31, 2023 and March 31, 2023 [Note 9]	24,999	24,999
Additional paid-in-capital	95,560,789	92,844,478
Accumulated other comprehensive income/(loss)	(251,888)	(152,797)
Accumulated deficit	(123,099,681)	(112,570,825)
TOTAL STOCKHOLDERS’ DEFICIENCY	(27,756,354)	(19,845,385)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY	5,486,218	6,510,544
Serie B Convertible Redeemable Preferred Stock [Member]
Mezzanine Equity
Series B Convertible Redeemable preferred stock, $0.001 par value, 600 and no shares authorized as of December 31, 2023 and March 31, 2023, respectively, 220 and no shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively [Note 9]	1,028,856
Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock, value	1	1
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock, value	$ 6	$ 6

About Biotricity Inc.

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

CEO	Dr. Waqaas Al-Siddiq Ph.D.
WEBSITE	biotricity.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	55

Biotricity Inc. Frequently Asked Questions

What is the ticker symbol for Biotricity Inc.? What does BTCY stand for in stocks?

BTCY is the stock ticker symbol of Biotricity Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biotricity Inc. (BTCY)?

As of Fri May 17 2024, market cap of Biotricity Inc. is 9.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTCY stock?

You can check BTCY's fair value in chart for subscribers.

What is the fair value of BTCY stock?

You can check BTCY's fair value in chart for subscribers. The fair value of Biotricity Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biotricity Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTCY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biotricity Inc. a good stock to buy?

The fair value guage provides a quick view whether BTCY is over valued or under valued. Whether Biotricity Inc. is cheap or expensive depends on the assumptions which impact Biotricity Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTCY.

What is Biotricity Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BTCY's PE ratio (Price to Earnings) is -0.67 and Price to Sales (PS) ratio is 0.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTCY PE ratio will change depending on the future growth rate expectations of investors.